According to European Medicines Agency, Zolgensma is indicated for treatment of children with biallelic pathogenic variants in the SMN1 gene and a clinical diagnosis of SMA Type 1, or asymptomatic children with biallelic SMN1 mutations and up to 3 copies of the SMN2 gene. The gene discussed is SMN1; the disease is spinal muscular atrophy, type 1.